Advancing RNA
Online/Digital
Advancing RNA is a Life Science Connect community focused on the rapidly evolving field of RNA-based therapeutics. It aims to provide valuable insights, discussions, and resources for professionals developing RNA-based drugs. Primary members of the community consist of individuals from biopharma organizations engaged in pre-BLA development, often in the pre-IND discovery stage. The community addresses various challenges in RNA therapy development, including analytical, quality, manufacturing, and regulatory issues. Additionally, Advancing RNA is positioned within the broader Life Science Connect network, allowing members to access additional resources as needed for their RNA therapy development journey. Source
Actions
Media Outlet details
| Scope | National |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesSimplify The Encapsulation Process Of Nucleic Acid Payloads With FDmiX Technology
Get more Advancing RNA insight with our FREE newsletter Enable a reliable, swift scale-up to cGMP manufacturing for mRNA encapsulation with the high-end FDmiX technology. Discover how to master challenges, streamline production, and enable faster, more predictable development of nucleic acid delivery systems.
mRNA Research Services To Accelerate Your Project
By Ilaria Pettinati, Ph.D., Group Lead Process Development - mRNA, and Alexander Schwenger, Ph.D., Head of Process Development - LNP Decisions made during mRNA research and discovery can influence the direction, cost, and complexity of downstream development.
The Early Advantage For mRNA
Lonza’s mRNA Research Services simplify this by providing end-to-end support, from mRNA synthesis to Lipid Nanoparticles (LNP) formulation - helping you reduce costs and accelerate development. Even if you haven’t considered mRNA for your protein, our experts can guide you through its potential.
10.14.26 -- Better Translatability. Higher Capping. Ultra-low dsRNA.
Get more Advancing RNA insight with our FREE newsletter Newsletter | October 14, 2026 A strong capping number can mask real problems: cap analog cost, dsRNA burden, and yield that swings with template and UTR design. See how AG-capped workflows hold up under process development pressure. T7-promoter workflows are easy to adopt, but familiarity can mask gaps in yield, dsRNA formation, capping flexibility, and translatability that surface only as a program reaches process development and scale-up.
10.14.26 -- What Oligo Manufacturing Risks Are We Underestimating?
CDMO Services: Customized Lipids & LNP Solutions Bringing your lipid-based therapies from early research into clinical and commercial manufacturing demands more than technical capability. It requires experience, flexibility, and seamless execution across development stages. Explore GMP-ready, fully connected CDMO services: From lipid manufacturing through LNP formulation, manufacturing, and Fill & Finish.
Exploring Technologies For cGMP Success With Encapsulation Of Nucleic Acid-Based Therapeutics Original
By Alexander Schwenger, Ph.D., Head of Process Development - LNP, and Telmo Gra├ža, Ph.D., Process and Technology Lead - mRNA Delivering mRNA therapeutics at clinical and commercial scale requires effective lipid nanoparticle (LNP) encapsulation, but the complexity of producing drug product under current good manufacturing practice (cGMP) conditions can be underestimated.
Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development Plan
By Robert Dream, consultant to the industry Oligonucleotide therapeutics have established a new therapeutic paradigm in which disease biology can be modulated directly at the RNA level.1 Antisense oligonucleotides and siRNAs can selectively alter RNA processing, promote degradation of target transcripts, or induce RNA interference. Nevertheless, systemic delivery remains a major limitation for many oligonucleotide medicines.
Recipharm Advanced Bio Capabilities Update September 2026: mRNA
Advancing RNA Therapeutics Through Integrated Development and Manufacturing RNA therapeutics are transforming the treatment landscape across infectious disease, oncology, rare disease, and gene editing, but their successful development requires coordinated expertise across plasmid production, RNA synthesis, formulation, analytics, and manufacturing.
Can Engineering The Passenger Strand Improve siRNA Performance?
By David R. Tabatadze, Ph.D., President and CEO, ZATA Pharmaceuticals, Inc. An siRNA therapeutic must accomplish more than bind its intended RNA target. After entering a cell, its guide strand must be loaded into the RNA-induced silencing complex (RISC), while the passenger strand must be discarded. When that selection is inefficient, less guide strand may be available for the intended activity, and passenger strand loading may contribute to unintended gene silencing.
Developing Custom GMP Lipids: A Patient-Driven Partnership
Webinar | October 8, 2026 A custom lipid can be well designed and still struggle to reach GMP-grade production. Closing that gap depends on how process development and manufacturing teams work together, and this virtual symposium brings both sides of one partnership into the same conversation. Experts from each function walk through the technical and operational milestones they reached together, from first design through scale-up to GMP manufacturing.